GlassScriptPhysician profile
Sara I Dever
NPI 1992990535
$2,958.17
in general payments reported to CMS, 2019-2025
22 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $645 · 2021: $595 · 2022: $993 · 2023: $220 · 2024: $126 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $447.09 | 2019-2025 | Nucala |
| Genzyme Corporation | $383.23 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $292.72 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $291.41 | 2019-2025 | Tezspire |
| Pfizer INC. | $251.55 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.67 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $130.23 | 2019-2023 | Dupixent |
| Optinose US, INC. | $119.05 | 2020-2022 | |
| Kaleo, INC. | $118.64 | 2019-2022 | |
| Genentech USA, INC. | $117.67 | 2019-2024 | Xolair |
| Alk-Abello, INC | $105.12 | 2019-2022 | |
| Csl Behring | $79.19 | 2019-2024 | Haegarda |
| Takeda Pharmaceuticals U.S.A., INC. | $76.83 | 2020-2022 | |
| Covis Pharma Gmbh | $61.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.20 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.32 | 2022 | |
| Phadia US INC. | $32.65 | 2020 | |
| Leo Pharma INC. | $27.62 | 2022 | |
| Incyte Corporation | $23.76 | 2022 | |
| Galderma Laboratories, L.P. | $22.92 | 2025 | Nemluvio |
| Circassia INC. | $22.63 | 2021 | |
| Biocryst US Sales Co., LLC | $21.19 | 2024 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Dever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.